Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Intersect ENT
Menlo Park, California, United Statesintersectent.com ↗
- Ownership
- Private
- Employees
- ~400
- Development stage
- Other
01
Overview
Intersect ENT developed and commercialized the first FDA-approved bioabsorbable steroid-eluting sinus stents for chronic rhinosinusitis. Its lead products—PROPEL family and SINUVA—demonstrated efficacy in reducing post-surgical inflammation and recurrent nasal polyps. The company’s devices deliver targeted anti-inflammatory therapy directly to the sinuses with established safety and effectiveness in multiple clinical trials.
- Therapeutic areas
- ImmunologyPulmonology
- Modalities
- DeviceDrug-device combinationSmall molecule
- Industry
- Implantable Medical Devices
02
Partnerships
No major external pharma/biotech partnerships disclosed; previously VC-backed
Beyond the preview
Go deeper on Intersect ENT.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intersect ENT.